BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has BARD1 Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BD1's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BD1 exceeded the Australian Healthcare industry which returned 0.7% over the past year.
Return vs Market: BD1 exceeded the Australian Market which returned -7.8% over the past year.
Price Volatility Vs. Market
How volatile is BARD1 Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StDo Institutions Own BARD1 Life Sciences Limited (ASX:BD1) Shares?
3 months ago | Simply Wall StIntroducing BARD1 Life Sciences (ASX:BD1), A Stock That Climbed 26% In The Last Year
3 months ago | Simply Wall StHave Insiders Been Buying BARD1 Life Sciences Limited (ASX:BD1) Shares This Year?
Is BARD1 Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BD1 is unprofitable, so we can't compare its PE Ratio to the AU Healthcare industry average.
PE vs Market: BD1 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BD1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BD1 is overvalued based on its PB Ratio (5.7x) compared to the AU Healthcare industry average (1.4x).
How is BARD1 Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BARD1 Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine BARD1 Life Sciences's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- BARD1 Life Sciences competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has BARD1 Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BD1 is currently unprofitable.
Growing Profit Margin: BD1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BD1 is unprofitable, and losses have increased over the past 5 years at a rate of 6.2% per year.
Accelerating Growth: Unable to compare BD1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BD1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (4.3%).
Return on Equity
High ROE: BD1 has a negative Return on Equity (-29.29%), as it is currently unprofitable.
How is BARD1 Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: BD1's short term assets (A$8.7M) exceed its short term liabilities (A$526.0K).
Long Term Liabilities: BD1's short term assets (A$8.7M) exceed its long term liabilities (A$31.7K).
Debt to Equity History and Analysis
Debt Level: BD1 is debt free.
Reducing Debt: BD1 currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BD1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BD1 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 26.8% each year
What is BARD1 Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BD1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BD1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BD1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BD1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BD1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of BARD1 Life Sciences Limited since November 7, 2016. Dr. Hinch is a biotechnology executive and consultant ...
CEO Compensation Analysis
Compensation vs Market: Leearne's total compensation ($USD316.32K) is about average for companies of similar size in the Australian market ($USD269.15K).
Compensation vs Earnings: Leearne's compensation has increased whilst the company is unprofitable.
|Chief Executive Officer||3.75yrs||AU$442.44k||no data|
|Managing Director||no data||AU$75.28k||1.64% |
|CFO & Company Secretary||0.083yr||no data||no data|
|Chief Operating Officer||0.083yr||no data||no data|
Experienced Management: BD1's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.
|Managing Director||no data||AU$75.28k||1.64% |
|Independent Non-Executive Director||1.17yrs||AU$2.14k||0.21% |
|Non-Executive Chairman||0.083yr||no data||no data|
|Independent Non-Executive Director||1.17yrs||AU$2.14k||0.24% |
|Non-Executive Director||0.58yr||no data||no data|
|Member of Advisory Board||3.08yrs||no data||no data|
|Non-Executive Director||0.083yr||no data||no data|
Experienced Board: BD1's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
BARD1 Life Sciences Limited's company bio, employee growth, exchange listings and data sources
- Name: BARD1 Life Sciences Limited
- Ticker: BD1
- Exchange: ASX
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$74.230m
- Shares outstanding: 2.39b
- Website: https://www.bard1.com
- BARD1 Life Sciences Limited
- Unit 202, 39 Mends Street
- Level 2
- South Perth
- Western Australia
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BD1||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jun 2016|
|EGQ||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 2016|
|BD1||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jun 2016|
BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a screening test fo ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/06 10:44|
|End of Day Share Price||2020/08/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.